Anti-AKT (clone W24V28) Recombinant Antibody Coupled Liposome (VS-1024-FY29) (CAT#: VS-1024-FY29)

The research on anti-Akt antibody-conjugated liposomes in the treatment of human colon cancer is still in the exploratory stage. Although the literature mentions some studies related to liposomes, such as the significant antitumor effects of CD44 antibody-modified liposomes in CD44-positive cancers, the specific effects of anti-Akt antibody-conjugated liposomes still require more experiments and clinical studies for validation.
Anti-Akt antibody-conjugated liposome is designed to target ischemic myocardium, which shows great potential for investigating enhanced cell survival and myocardial repair. By boosting the activity of the Akt signaling pathway, these liposomes may foster the survival and viability of cardiac cells.
Anti-AKT antibody conjugated liposomes hold significant potential for targeted therapy in adrenocortical carcinoma by enhancing the delivery of therapeutic agents directly to cancer cells that express AKT. This targeted approach could improve the efficacy of treatment while minimizing off-target effects, thereby reducing systemic toxicity. Additionally, these liposomes can serve as a tool for monitoring treatment responses through imaging techniques, which can help in evaluating their therapeutic impact. Ultimately, the use of these specialized liposomes may lead to novel therapeutic strategies and improved outcomes for patients suffering from this aggressive cancer type.
Anti-AKT antibody conjugated liposomes hold significant promise in research for targeting metastatic fibrosarcoma due to their ability to deliver therapeutic agents directly to cancer cells expressing the AKT pathway. By specifically binding to AKT, these liposomes can enhance the selectivity and efficacy of treatments, potentially leading to improved clinical outcomes with reduced side effects. Furthermore, this targeted approach facilitates the investigation of the mechanistic roles of AKT in fibrosarcoma progression and resistance to therapies.